SEOUL, South Korea, Feb. 29, 2016 /PRNewswire/ -- STC-Stem Cell Treatment & Research Institute ("STRI" or "the Company") Chairman Kye-ho Lee announced the Company's registration of a local patent on the method to mass produce its pluripotent stem cells without side effects. The Company plans to follow the patent application and registration process in 146 different countries.
The patented technology uses latest cell differentiation and cultivation technology, along with low molecular weight compound extracted from a natural compound. This enables the mass production of a mesenchymal stem cell and pluripotent stem cells without side effects.
"Using mesenchymal stem cells as source and treating them with a low molecular weight compound derived from a natural compound, we were able to discover a pluripotent stem cell without side effects. Its significance lies in being able to mass produce such pluripotent stem cells without side effects while continuing to maintain its functionality," remarked Dr. Alex Lee from STRI. He added, "This technology will enable us to discover a more efficient and economic means of cell therapy."
Such mass production will be available not only for the pluripotent stem cell itself but also for its derived cells, including the pancreatic beta cell, hepatocyte, neurocyte, chondrocyte and osteoblast. This discovery offers a whole new paradigm in the field of cell therapy that is not only effective but also highly approachable.
Chairman Kye-ho Lee of STRI remarked, "The significance of the patented technology lies in it overcoming the limitations faced by research & development that uses conventional Induced Pluripotent Stem Cell (iPSC) technology and is expected to bring a whole new dimension to cell therapy development."
For further information, please contact: